Description
Implementation of Parameters Control after acute coronary syndrome (ACS). Study performed in 4 Slovak cardiology centres aimed to achieve better control of laboratory parameters and heart function in patients who suffered acute coronary syndrome. Preliminary results showed better control of LDL cholesterol after one year in comparison with existing data from Slovak registry of patients after acute coronary syndrome (SLOVAKS) from previous years. First data showed higher increase of left ventricle ejection fraction. Results have been achieved due to more intensified and more frequent controls after ACS in patients still not optimally treated until they will achieve target level.Program launch date
2024- in progressResponsible entity
Slovak Society of CardiologyAvailable results and quality metrics
Study is at the end of recruitment phase. Preliminary results presented at Slovak Society Cardiology congress showed only improved trends - majority of patients still did not reach final visit.Limitations / comments
Limitations at the beginning of IMPAKS study were prescription and indication criteria for PCSK9 inhibitors and inclisiran. However, shortly before start of study those limitations were removed for inclisiran only in all patients after ACS not achieving target level of LDL-cholesterol (below 1.4 mmol/l). Ability to prescribe inclisiran helps major part of patients to achieve target levels of LDL cholesterol. Based on existing epidemiological data and data from clinical trials it is possible to expect lowering of cardiovascular morbidity and mortality in this group of patients.